Avricore Health Inc. (AVCRF)

Avricore Health Inc. operates in the unsexy but functional corner of healthcare where pharmacy and diagnostics intersect. The company’s core business is straightforward: acquire and develop early-stage technologies that solve real problems for community pharmacies, with its primary product being HealthTab™, a turnkey point-of-care testing platform designed to transform pharmacies into diagnostic hubs.

The HealthTab system is built around Abbott’s Afinion 2™ analyzer, which can test up to 27 different biomarkers on-site—including glucose, lipid panels, and other screening markers relevant to common chronic conditions like diabetes. Instead of patients waiting days for lab results or traveling to diagnostic facilities, they can walk into a pharmacy, run a test, and get actionable results within minutes. For pharmacies, this creates a new revenue stream and increases customer value; for patients, it brings health screening closer to where people already are.

The business model relies on two revenue engines: hardware and recurring testing services. Pharmacies pay to install the system, and then Avricore earns ongoing margins from supplies, test kits, and platform fees as pharmacies run diagnostics. The company signed a pilot agreement with Shoppers Drug Mart, one of Canada’s largest pharmacy chains, which signals interest from major players in the pharmacy sector. The Canadian roots (headquartered in Vancouver, British Columbia) matter for regulatory approval and market entry, though the OTC listing exposes the company to U.S. retail investors.

Avricore sits at the intersection of two healthcare mega-trends: the shift of care delivery away from centralized facilities and the growing role of pharmacists as primary healthcare touchpoints. Whether the company can scale HealthTab beyond boutique pilot programs and into meaningful revenue depends on execution in network expansion, unit economics, and the willingness of pharmacy chains to prioritize diagnostic services as a core business line rather than a one-off feature. The technology is not proprietary (Abbott is a partner, not exclusive), so competitive moats rest on distribution, partnerships, and operational efficiency rather than patent protection.